LY 2603618

Key Product Details

Product Description

LY 2603618 is a potent and selective Chk1 inhibitor (IC₅₀ = 7 nM). Inhibits Chk1 autophosphorylation. Induces cell cycle arrest in the G₂/M phase and induces the DNA damage response in lung cancer cells. Inhibits growth of NSCLC xenografts in mice when administered in combination with Pemetrexed (Cat.No. 6185).

Product Specifications for LY 2603618

The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.

Solubility

Preparing Stock Solutions for LY 2603618

The following data is based on the product molecular weight 436.30.

Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which all affect the solvent volumes required to prepare stock solutions.

Select a batch to recalculate based on the batch molecular weight:

1 Recalculate

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
0.2 mM	11.46 mL	57.30 mL	114.60 mL
1 mM	2.29 mL	11.46 mL	22.92 mL
2 mM	1.15 mL	5.73 mL	11.46 mL
10 mM	0.23 mL	1.15 mL	2.29 mL

Calculators

Background References

References are publications that support the biological activity of the product.

• Calvo Preclinical analyses and phase I evaluation of LY2603618 administered in combination with pemet. and cisp. in patients with advanced cancer. Invest.New Drugs 2014 PMID: 24942404
• Wang The checkpoint 1 kinase inhibitor LY2603618 induces cell cycle arrest, DNA damage response and autophagy in cancer cells. Apoptosis 2014 PMID: 24928205

Product Documents for LY 2603618